Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 16, 2022

BUY
$0.21 - $0.32 $12,600 - $19,200
60,000 Added 1794.26%
63,344 $14,000
Q2 2022

Aug 16, 2022

BUY
$0.26 - $0.64 $869 - $2,140
3,344 New
3,344 $1,000
Q1 2022

May 16, 2022

SELL
$0.52 - $1.0 $6,730 - $12,944
-12,944 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$0.85 - $1.33 $14,365 - $22,477
-16,900 Reduced 56.63%
12,944 $13,000
Q3 2021

Nov 16, 2021

SELL
$1.03 - $1.41 $91,413 - $125,138
-88,751 Reduced 74.84%
29,844 $39,000
Q2 2021

Aug 16, 2021

SELL
$1.04 - $1.5 $1,410 - $2,034
-1,356 Reduced 1.13%
118,595 $130,000
Q1 2021

May 17, 2021

BUY
$0.84 - $2.16 $5,139 - $13,214
6,118 Added 5.37%
119,951 $140,000
Q4 2020

Feb 16, 2021

BUY
$0.65 - $1.11 $12,891 - $22,014
19,833 Added 21.1%
113,833 $98,000
Q3 2020

Nov 17, 2020

BUY
$0.48 - $0.84 $6,720 - $11,760
14,000 Added 17.5%
94,000 $78,000
Q2 2020

Aug 14, 2020

BUY
$0.43 - $0.74 $34,400 - $59,200
80,000 New
80,000 $58,000

Others Institutions Holding NMTR

About 9 METERS BIOPHARMA, INC.


  • Ticker NMTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,955,400
  • Market Cap $259K
  • Description
  • 9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...
More about NMTR
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.